Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 31.19 USD 1.3% Market Closed
Market Cap: 1B USD
Have any thoughts about
Collegium Pharmaceutical Inc?
Write Note

Collegium Pharmaceutical Inc
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Collegium Pharmaceutical Inc
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
Collegium Pharmaceutical Inc
NASDAQ:COLL
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accumulated Depreciation
-$28.8B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Bristol-Myers Squibb Co
NYSE:BMY
Accumulated Depreciation
-$4.8B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
Pfizer Inc
NYSE:PFE
Accumulated Depreciation
-$16.6B
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Accumulated Depreciation
-$19.1B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Accumulated Depreciation
-$11.8B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
No Stocks Found

Collegium Pharmaceutical Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
47.46 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

Back to Top